These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 30811663)

  • 1. Eradication rate of Helicobacter pylori reinfection in Korea: A retrospective study.
    Choi YK; Ahn JY; Won SH; Jung K; Na HK; Jung KW; Kim DH; Lee JH; Choi KD; Song HJ; Lee GH; Jung HY
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1696-1702. PubMed ID: 30811663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eradication Rate of
    Liu RP; Romero R; Sarosiek J; Dodoo C; Dwivedi AK; Zuckerman MJ
    South Med J; 2018 Jan; 111(1):51-55. PubMed ID: 29298370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
    Lee HJ; Kim JI; Lee JS; Jun EJ; Oh JH; Cheung DY; Chung WC; Kim BW; Kim SS
    World J Gastroenterol; 2015 Jan; 21(1):351-9. PubMed ID: 25574111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Jul; 21(26):8132-9. PubMed ID: 26185386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH; Lee DH; Lee ST; Kim N; Park YS; Shin CM; Song IS
    World J Gastroenterol; 2015 Dec; 21(46):13124-31. PubMed ID: 26673999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea.
    Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Kim JM; Jung HC
    Helicobacter; 2013 Apr; 18(2):135-42. PubMed ID: 23066652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Helicobacter pylori eradication with moxifloxacin-containing therapy following failed first-line therapies in South Korea.
    Kang KK; Lee DH; Oh DH; Yoon H; Shin CM; Park YS; Kim N; Jung HC
    World J Gastroenterol; 2014 Jun; 20(22):6932-8. PubMed ID: 24944485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 10-day levofloxacin bismuth-based quadruple therapy and levofloxacin-based triple therapy for Helicobacter pylori.
    Wu TS; Hsu PI; Kuo CH; Hu HM; Wu IC; Wang SSW; Chen YH; Wu DC; Su WW; Kuo FC
    J Dig Dis; 2017 Sep; 18(9):537-542. PubMed ID: 28644575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients.
    Lim NR; Kim J; Chung WC
    Helicobacter; 2024; 29(1):e13036. PubMed ID: 37985416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
    Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
    Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furazolidone-based triple and quadruple eradication therapy for Helicobacter pylori infection.
    Xie Y; Zhu Y; Zhou H; Lu ZF; Yang Z; Shu X; Guo XB; Fan HZ; Tang JH; Zeng XP; Wen JB; Li XQ; He XX; Ma JH; Liu DS; Huang CB; Xu NJ; Wang NR; Lu NH
    World J Gastroenterol; 2014 Aug; 20(32):11415-21. PubMed ID: 25170230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Helicobacter pylori eradication rates by first-line triple therapy and related factors in eradication therapy.
    Kim SE; Park MI; Park SJ; Moon W; Choi YJ; Cheon JH; Kwon HJ; Ku KH; Yoo CH; Kim JH; Lee GW; Song SE
    Korean J Intern Med; 2015 Nov; 30(6):801-7. PubMed ID: 26552455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line rescue treatment of
    Lin TF; Hsu PI
    World J Gastroenterol; 2018 Oct; 24(40):4548-4553. PubMed ID: 30386104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
    Lee JM; Breslin NP; Hyde DK; Buckley MJ; O'Morain CA
    Aliment Pharmacol Ther; 1999 Apr; 13(4):489-96. PubMed ID: 10215733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of 14-d vs 7-d moxifloxacin-based triple regimens for second-line Helicobacter pylori eradication.
    Hwang JJ; Lee DH; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 May; 21(18):5568-74. PubMed ID: 25987781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow up of Helicobacter pylori IgG serology after eradication and reinfection rate of H. pylori in South Korea.
    Lee JH; Kim N; Chung JI; Kang KP; Lee SH; Park YS; Hwang JH; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Helicobacter; 2008 Aug; 13(4):288-94. PubMed ID: 18665939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes after Helicobacter pylori eradication with second-line, bismuth-containing quadruple therapy in Korea.
    Cheon JH; Kim N; Lee DH; Kim JM; Kim JS; Jung HC; Song IS
    Eur J Gastroenterol Hepatol; 2006 May; 18(5):515-9. PubMed ID: 16607147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trend in the Eradication Rates of
    Park JS; Park JE; Oh BS; Yoon BW; Kim HK; Lee JW; Kim NH; Cho WS; Woo YS; Jahng J; Kim YS
    Korean J Gastroenterol; 2017 Nov; 70(5):232-238. PubMed ID: 29161792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eradication rate and histological changes after Helicobacter pylori eradication treatment in gastric cancer patients following subtotal gastrectomy.
    Hwang JJ; Lee DH; Kang KK; Lee AR; Yoon H; Shin CM; Park YS; Kim N
    World J Gastroenterol; 2015 Apr; 21(13):3936-43. PubMed ID: 25852279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
    Grgov S; Tasić T; Radovanović-Dinić B; Benedeto-Stojanov D
    Vojnosanit Pregl; 2016 Nov; 73(11):1044-9. PubMed ID: 29328644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.